Mutation of Proteolipid Protein 1 Gene: From Severe Hypomyelinating Leukodystrophy to Inherited Spastic Paraplegia

Archive ouverte

Khalaf, Guy | Mattern, Claudia | Begou, Mélina | Boespflug-Tanguy, Odile | Massaad, Charbel | Massaad-Massade, Liliane

Edité par CCSD ; MDPI -

International audience. Pelizaeus–Merzbacher Disease (PMD) is an inherited leukodystrophy affecting the central nervous system (CNS)—a rare disorder that especially concerns males. Its estimated prevalence is 1.45–1.9 per 100,000 individuals in the general population. Patients affected by PMD exhibit a drastic reduction or absence of myelin sheaths in the white matter areas of the CNS. The Proteolipid Protein 1 (PLP1) gene encodes a transmembrane proteolipid protein. PLP1 is the major protein of myelin, and it plays a key role in the compaction, stabilization, and maintenance of myelin sheaths. Its function is predominant in oligodendrocyte development and axonal survival. Mutations in the PLP1 gene cause the development of a wide continuum spectrum of leukopathies from the most severe form of PMD for whom patients exhibit severe CNS hypomyelination to the relatively mild late-onset type 2 spastic paraplegia, leading to the concept of PLP1-related disorders. The genetic diversity and the biochemical complexity, along with other aspects of PMD, are discussed to reveal the obstacles that hinder the development of treatments. This review aims to provide a clinical and mechanistic overview of this spectrum of rare diseases.

Suggestions

Du même auteur

Therapeutic potential of siRNA PMP22-SQ nanoparticles for Charcot-Marie-Tooth 1A neuropathy in rodents and non-human primates

Archive ouverte | Boutary, Suzan | CCSD

International audience. Small interfering RNA (siRNA) has shown promising results for the treatment of Charcot-Marie-Tooth disease 1A (CMT1A) caused by overexpression of peripheral myelin protein (PMP22), leading to...

Optimizing Structure and Activity of the Squalenoyl-siRNA Nanoparticles

Archive ouverte | Boutary, Suzan | CCSD

International audience. siRNA is a promising tool for targeted therapy. Previously we conjugated the siRNA to Squalene (SQ) by copperfree click chemistry, which has been proven to successfully deliver siRNA to tumor...

Hypoxia down-regulates CCAAT/enhancer binding protein-alpha expression in breast cancer cells.

Archive ouverte | Seifeddine, Ramzi | CCSD

International audience. The transcription factor CCAAT/enhancer binding protein-alpha (C/EBP alpha) is involved in the control of cell differentiation and proliferation, and has been suggested to act as a tumor supp...

Chargement des enrichissements...